कृपया अन्य खोज का प्रयास करें
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Lori Anne Kunkel | 63 | 2018 | Member of Scientific Advisory Board |
Isabel Aguilera Navarro | 61 | 2015 | Independent Director |
Antonio Fornieles Melero | - | 2015 | Independent Director |
Ramon Adell Ramon | 63 | 2015 | Independent Director |
Josep Maria Echarri Torres | - | - | Director |
Jose Luis Molinuevo | - | - | Member of Scientific Advisory Board |
Felipe Prosper Cardoso | - | - | Member of Scientific Advisory Board |
Tamara Maes | - | 2000 | VP of the Board & President of Scientific Advisory Board |
Leon Hooftman | - | - | Member of Scientific Advisory Board |
Carlos Manuel Buesa Arjol | - | 2000 | Co-Founder, Chairman, CEO & President |
Manuel López-Figueroa | - | 2020 | Lead Independent Director |
Howard Martin Fillit | - | - | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है